Abstract:BackgroundAutoantibodies to citrullinated protein (ACPA; measured as anti-CCP; aCCP) and rheumatoid factor (RF) appear years before clinical onset of RA and are essential tools in today’s classification criteria for RA. In animal models, antibodies to joint specific proteins (JP) can induce arthritis, and they are also present at onset of RA [1]. As there is a need for increased precision for early diagnosis of RA as well as identification of different subtypes of the disease, we aim to assess whether autoantibodies to native or modified JP can be used for early and precise diagnosis of RA.ObjectivesTo study whether antibodies to JP, alone or in combination with ACPA/RF, could increase the diagnostic sensitivity and specificity in untreated early (ue)RA patients.MethodsAntibodies to JP were analysed in serum from patients in three independent ueRA cohorts as well as from population controls without rheumatic diseases (WINGA, Gothenburg and MFM-ÅUS, Malmö n=1062). ERAp (n=66), the smallest and most recent cohort was chosen for screening, and BARFOT and TIRA-2 (n=1939) for validation. We have developed a bead-based multianalyte flow immunoassay [2] and screened approx. 350 peptides derived from JPs of interest. We included monoclonal antibodies as assay calibrators and determined limit of detection (LoD). To assess positivity for autoantibodies to JP of interest above LoD, we used 5MAD (median absolute deviation) of the control populations as the cut-off.ResultsIn the ERAp cohort, 5 autoantibodies discriminated RA patients from controls with 81% sensitivity and 100% specificity (Table 1). The same autoantibodies had 68% sensitivity and 98% specificity in the combined BARFOT and TIRA-2 cohorts. Together with RF and aCCP, only 2 of the 5 autoantibodies added statistically significant diagnostic value, increasing the sensitivity from 48% to 61% with 99% specificity. In aCCP- and RF-negative ueRA patients (n=536), the novel biomarkers identified 22.5% of the patients with 99% specificity compared to controls.Table 1.Diagnostic capacity of the joint-specific antibodiesTest panelPerformanceGroup of patientsaCCP+RF+JP+SensitivitySpecificityAUC(ROC)ERApAll patients (n=66)--X81%100%89%RF and aCCP-neg patients (n=7)1------BARFOT and TIRA-2, combined dataAll patients (N=1939)--X68%98%86%All patients (N=1939)X--58%99%78%All patients (N=1939)2XX-48%100%84%All patients (N=1939)2, 3XXX61%99%86%RF and/or aCCP-pos patients (N=1403)--X84%99%93%RF and aCCP-neg patients (N=536)--X22%99%67%RA, literature valuesAnti-CCP testXN/AN/A53–71%95–96%N/A1Not analysed due to lack of power2This patient population is both aCCP+ and RF+3Only 2 of the 5 autoantibodies added statistically significant to the diagnostic valueAUC, Area under the curve; ROC, receiver operating characteristic curve; N/A, not applicable. Controls without rheumatic diseases: N=935 for BARFOT / TIRA-2 and N=27 for ERAp.ConclusionAutoantibodies to JP discriminate ueRA patients better then aCCP and RF alone and add an increased diagnostic value in particular for seronegative patients.References[1]Holmdahl, R., V. Malmstrom, and H. Burkhardt, Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol, 2014. 44(6): p. 1593-9.[2]Viljanen, J., et al., Synthesis of an Array of Triple-Helical Peptides from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid Arthritis. ACS Chem Biol, 2020. 15(9): p. 2605-2615. Correction: ACS Chem Biol, 2020. 15(11): p. 3072AcknowledgementsBARFOT study group.Disclosure of InterestsErik Lönnblom: None declared, Monica Leu Agelii: None declared, Outi Sareila Employee of: Part time employee in Vacara AB, Ingiäld Hafström: None declared, Maria Andersson: None declared, Lei Cheng: None declared, Göran Bergström: None declared, Anna-Karin H Ekwall: None declared, Anna Rudin: None declared, Alf Kastbom: None declared, Christopher Sjowall: None declared, Bingze Xu: None declared, Lennart T.H. Jacobsson: None declared, Johan Viljanen: None declared, Jan Kihlberg: None declared, Inger Gjertsson: None declared, Rikard Holmdahl Shareholder of: Rikard Holmdahl the founder of Vacara AB.

Synovial Class-Ii Antigen Expression and Immune-Complex Formation in Rheumatoid-Arthritis

Studies on Collagen II Induced Arthritis in Mice and Rats

T173 PERSISTENT PAIN-LIKE BEHAVIOR AND REDUCED LOCOMOTION, BUT TRANSIENT JOINT INFLAMMATION, IN THE COLLAGEN ANTIBODY-INDUCED ARTHRITIS (CAIA) MOUSE MODEL

B Cell Presentation of Cartilage Type II Collagen to T Cells

Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue.

Associations Between Genetic Variation in the Targets of Low-Density Lipoprotein-Lowering Drugs and Rheumatoid Arthritis

THU0066 IN EARLY RHEUMATOID ARTHRITIS ANTI-CITRULLINATED PEPTIDE ANTIBODIES ASSOCIATE WITH LOWER NUMBER OF AFFECTED JOINTS, AND IGM RHEUMATOID FACTOR WITH SYSTEMIC INFLAMMATION IN AN ANTI-CITRULLINE DEPENDENT MANNER

POS0562 AUTOANTIBODIES TO JOINT PROTEINS AS NOVEL BIOMARKERS FOR THE DIAGNOSIS OF UNTREATED EARLY RHEUMATOID ARTHRITIS

Experimental Allergic Neuritis: Dynamics of Ia-expressing Cells, T Lymphocytes of Different Subsets in Peripheral Nerve Tissue and Serum IgG Response

Expression of Interleukin-18, Il-18bp, and Il-18r in Serum, Synovial Fluid, and Synovial Tissue in Patients with Rheumatoid Arthritis

Clonal associations between lymphocyte subsets and functional states in rheumatoid arthritis synovium

Early Recognition of Relapsing Polychondritis: Comment on the Article by Ferrada Et Al

OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY

Immunoregulation in Arthritis. A Review on Synovial Immune Reactions in RA and in Some Experimental Animal Models for Arthritis.

SAT0031 Detection and Isolation of Antigen Specific B Cells in Patients with Rheumatoid Arthritis

Multifunctional T Cell Reactivity to Native and Glycosylated Type-II Collagen in Rheumatoid Arthritis.

Aire-mediated Central Tolerance Includes Nave but Not Post-Translational Modified Self-Antigens

Immunophenotypic Landscape of synovial tissue in rheumatoid arthritis: Insights from ACPA status

Arthritis Resist IDO-Mediated Inhibition Synovial Autoreactive T Cells in Rheumatoid

Cartilage Autoimmunity in Experimental Models for Rheumatoid Arthritis

This information is current as HTRA 1 Expression in Rheumatoid Arthritis on Protease γ The Inhibitory Effect of IFN-and